$PULM News

Pulmatrix Q1 EPS $(0.32) Up From $(0.50) YoY

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Pulmatrix Signs Agreement To Acquire Eos SENOLYTIX; Financial Terms Undisclosed

Trading Halt: Halted at 7:59:18 a.m. ET - Trading Halt: Halt News Pending

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

Pulmatrix shares are trading lower after a planned acquisition was rejected.

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Cullgen Cancels Planned Merger With Pulmatrix; Pulmatrix To Continue Search For Acquisition

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix And Cullgen Agree To Waive 'No Solicitation' Clause In Merger Agreement, Granting Each Other Waivers To Explore Alternatives

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen

Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY